Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Emerging Biopharma
Biotech
Assembly, Context and Innate add to pile of dumped R&D prospects
The latest set of earnings reports brought news of more drug programs that are being stopped or deprioritized.
Nick Paul Taylor
Mar 23, 2023 8:00am
Fierce Biotech Fundraising Tracker: Switch, Allorion and more
Mar 22, 2023 11:00am
89bio hits primary goals in midphase NASH trial, plots phase 3
Mar 22, 2023 8:31am
Flare fires up with $123M series B and 3 Big Pharmas in tow
Mar 22, 2023 6:30am
BeiGene lets option on Leap’s immuno-oncology candidate lapse
Mar 17, 2023 8:50am
With $105M and Big Pharma backing, Mediar takes aim at fibrosis
Mar 15, 2023 8:21am
More News
Why do so many biotechs face being kicked off the Nasdaq?
Mar 14, 2023 9:55am
UPDATE: SVB failure sends shock waves across biotech industry
Mar 10, 2023 11:31am
Flagship fledging fetches $50M to fire drugs at specific organs
Mar 7, 2023 9:15am
Third Rock, J&J neuroscience spinout Rapport arrives with $100M
Mar 7, 2023 9:05am
See more stories
